Literature DB >> 15234059

3D CT-based high-dose-rate breast brachytherapy implants: treatment planning and quality assurance.

Rupak K Das1, Rakesh Patel, Hiral Shah, Heath Odau, Robert R Kuske.   

Abstract

PURPOSE: Although accelerated partial breast irradiation (APBI) as the sole radiation modality after lumpectomy has shown promising results for select breast cancer patients, published experiences thus far have provided limited information on treatment planning methodology and quality assurance measures. A novel three-dimensional computed tomography (CT)-based treatment planning method for accurate delineation and geometric coverage of the target volume is presented. A correlation between treatment volume and irradiation time has also been studied for quality assurance purposes. METHODS AND MATERIALS: Between May 2002 and January 2003, 50 consecutive patients underwent an image-guided interstitial implant followed by CT-based treatment planning and were subsequently treated with APBI with a high-dose-rate (HDR) brachytherapy remote afterloader. Target volume was defined as the lumpectomy cavity +2 cm margin modified to >/=5 mm to the skin surface. Catheter reconstruction, geometric optimization, and manual adjustment of irradiation time were done to optimally cover the target volume while minimizing hot spots. Dose homogeneity index (DHI) and percent of target volume receiving 100% of the prescription dose (32 Gy in 8 fractions or 34 Gy in 10 fractions) was determined. Additionally, the correlation between the treatment volume and irradiation time, source strength, and dose was then analyzed for manual verification of the HDR computer calculation.
RESULTS: In all cases, the lumpectomy cavity was covered 100%. Target volume coverage was excellent with a median of 96%, and DHI had a median value of 0.7. For each plan, source strength times the treatment time for every unit of prescribed dose had an excellent agreement of +/-7% to the Manchester volume implant table corrected for modern units.
CONCLUSIONS: CT-based treatment planning allowed excellent visualization of the lumpectomy cavity and normal structures, thereby improving target volume delineation and optimal coverage, relative to conventional orthogonal film dosimetry. Using the Manchester volume implant table calculated irradiation time can be used as quality assurance for the HDR computed time. Thus dosimetric quality assurance and adequate target volume coverage can be concurrently confirmed, allowing prospective evaluation and optimization of implants.

Entities:  

Mesh:

Year:  2004        PMID: 15234059     DOI: 10.1016/j.ijrobp.2004.03.030

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  Quality assessment of interstitial implants in high- dose- rate brachytherapy after lumpectomy in patients of early stage breast cancer.

Authors:  Samrat Dutta; Suresh C Sharma; Rajinder Singh; Rakesh Kapoor; Arun S Oinam; Anoop Bhardwaj; Pradeep Goswami
Journal:  Indian J Surg Oncol       Date:  2011-03-24

Review 2.  Brachytherapy in the treatment of breast cancer.

Authors:  Xinna Deng; Haijiang Wu; Fei Gao; Ye Su; Qingxia Li; Shuzhen Liu; Jianhui Cai
Journal:  Int J Clin Oncol       Date:  2017-06-29       Impact factor: 3.402

3.  A Retrospective Six Years Analysis of Survival and Late Morbidity of Post-operative Gynaecological Malignancy Treated with External Radiotherapy Followed by Brachytherapy in Medical College & Hospitals, Kolkata.

Authors:  Sourav Sau; Suparna Ghosh; Shila Mitra; Amitava Manna; Bidyut Mondal; Koushik Ghosh
Journal:  J Obstet Gynaecol India       Date:  2013-04-19

Review 4.  Current status and perspectives of brachytherapy for breast cancer.

Authors:  Csaba Polgár; Tibor Major
Journal:  Int J Clin Oncol       Date:  2009-02-20       Impact factor: 3.402

5.  Evaluation of radiograph-based interstitial implant dosimetry on computed tomography images using dose volume indices for head and neck cancer.

Authors:  Ritu Raj Upreti; S Dayananda; R L Bhalawat; Girish N Bedre; D D Deshpande
Journal:  J Med Phys       Date:  2007-04

6.  3D-CT implanted interstitial brachytherapy for T2b nasopharyngeal carcinoma.

Authors:  Yu-Feng Ren; Yuan-Hong Gao; Xin-Ping Cao; Wei-Jun Ye; Bin S Teh
Journal:  Radiat Oncol       Date:  2010-11-23       Impact factor: 3.481

7.  3D-image-guided high-dose-rate intracavitary brachytherapy for salvage treatment of locally persistent nasopharyngeal carcinoma.

Authors:  Yu-Feng Ren; Xin-Ping Cao; Jia Xu; Wei-Jun Ye; Yuan-Hong Gao; Bin S Teh; Bi-Xiu Wen
Journal:  Radiat Oncol       Date:  2013-07-05       Impact factor: 3.481

8.  Assessment of dose homogeneity in conformal interstitial breast brachytherapy with special respect to ICRU recommendations.

Authors:  Tibor Major; Georgina Fröhlich; Csaba Polgar
Journal:  J Contemp Brachytherapy       Date:  2011-09-30

9.  Endoscope-guided interstitial intensity-modulated brachytherapy and intracavitary brachytherapy as boost radiation for primary early T stage nasopharyngeal carcinoma.

Authors:  Xiang-Bo Wan; Rou Jiang; Fang-Yun Xie; Zhen-Yu Qi; Ai-Ju Li; Wei-Jun Ye; Yi-Jun Hua; Yu-Liang Zhu; Xiong Zou; Ling Guo; Hai-Qiang Mai; Xiang Guo; Ming-Huang Hong; Ming-Yuan Chen
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

Review 10.  Review of clinical brachytherapy uncertainties: analysis guidelines of GEC-ESTRO and the AAPM.

Authors:  Christian Kirisits; Mark J Rivard; Dimos Baltas; Facundo Ballester; Marisol De Brabandere; Rob van der Laarse; Yury Niatsetski; Panagiotis Papagiannis; Taran Paulsen Hellebust; Jose Perez-Calatayud; Kari Tanderup; Jack L M Venselaar; Frank-André Siebert
Journal:  Radiother Oncol       Date:  2013-11-30       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.